Biochemical Pharmacology Discussion Group
The New York Academy of Sciences
Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.
DONATEPosted November 18, 2019
Many disease-causing proteins cannot be targeted with traditional pharmacological approaches. As a result, more than 85% of the human proteome is “undruggable.” But in recent years, a novel technology called proteolysis-targeting chimeras (PROTACs) has emerged as a method to target and degrade such disease proteins. PROTACs are bifunctional small molecules that bring together a target protein and an E3-ubiquitin ligase, which leads to degradation of the targeted protein by the proteasome. The advantage is that PROTACs can degrade proteins regardless of their function, making it possible to target mutated or overexpressed proteins. Additionally, they can be designed into effective oral agents, making them therapeutically viable.
Learn more about the latest advances in targeted protein degradation and the benefits of this approach over traditional inhibitors in this summary of our September 24, 2019 symposium.